Treating Men With Overactive Bladder Nonresponsive to Antimuscarinics
Clinical and urodynamic criteria for antimuscarinic nonresponse in men are needed along with more quality research on treatment alternatives.
Clinical and urodynamic criteria for antimuscarinic nonresponse in men are needed along with more quality research on treatment alternatives.
Researchers conducted meta-analyses to investigate the real rates of persistence and adherence to overactive bladder drug therapies and moderating factors.
Higher potassium variability in patients with advanced CKD prior to starting dialysis may serve as a clinically important prognostic marker for mortality after transitioning to dialysis, according to investigators.
Perioperative transfusion of blood products was not associated with worse clinical outcomes or allosensitization in a study of selected kidney transplant recipients.
Higher cardiovascular morbidity was associated with more severe urge urinary incontinence and worse quality of life.
A meta-analysis evaluated the efficacy and safety of imidafenacin for overactive bladder induced by benign prostatic hyperplasia.
Study data illustrate the potential benefits of controlling serum phosphate, intact parathyroid hormone, and calcium levels in patients with nondialysis-dependent chronic kidney disease.
In a large US study, only half of patients with stage 3, 4, and 5 had undergone PTH retesting at 12, 8, and 4.5 months, respectively, after treatment with vitamin D sterols, in line with KDIGO guidelines.
Patterns of disease spread varied significantly among patients with clear cell, papillary, and chromophobe renal cell carcinoma and may reflect differences in disease biology, according to investigators.
Previous research correlates high parathyroid hormone levels with left ventricular hypertrophy in patients with kidney failure.